The Saudi Journal of Medical Insights

Background: The limitations of conventional biomarkers (e.g., PSA, CA-125), which often lack the sensitivity and
specificity for early, subclinical disease detection, create a significant diagnostic gap. This review synthesizes evidence on
novel biomarkers discovered via high-throughput omics technologies and evaluates their potential to revolutionize early
diagnosis.
Methods: A comprehensive literature review was conducted, synthesizing findings from key studies and clinical trials
referenced in this field. The analysis focuses on the mechanistic roles and clinical validation data of promising biomarker
classes, including circulating tumor DNA (ctDNA), microRNAs (miRNAs), exosomes, and metabolites.
Results: Novel biomarkers demonstrate a marked improvement in diagnostic performance. ctDNA assays can detect cancer
specific mutations with high specificity, with some studies achieving sensitivity and specificity ranges of 85-99% for
monitoring minimal residual disease. miRNA signatures, leveraging panels of multiple molecules, have shown the ability
to distinguish cancer patients from healthy controls with sensitivities and specificities often exceeding 90% in validation
cohorts. Metabolomic profiles have identified antecedent memory impairment in Alzheimer's disease with an accuracy of
over 90% in prospective studies. These biomarkers enable detection years before clinical manifestation, fundamentally
shifting the diagnostic paradigm from reactive to proactive.
Conclusion: Biomarkers such as ctDNA, miRNAs, and metabolites represent a transformative advance for early disease
detection. They offer a direct window into pathogenic processes, with the potential to intercept diseases like cancer and
Alzheimer's at their inception. However, their clinical implementation requires rigorous validation in large, diverse cohorts,
standardized protocols, and frameworks to address cost and equitable access. Successfully navigating these translational
challenges is essential for integrating these tools into a sustainable model of precision preventive medicine.